Cyclo-Oxygenase-2 InhibitorsWhen Should They Be Used in the Elderly?

被引:0
|
作者
Ruth Savage
机构
[1] University of Otago,New Zealand Pharmacovigilence Centre, Department of Preventive and Social Medicine
来源
Drugs & Aging | 2005年 / 22卷
关键词
Ibuprofen; Celecoxib; Naproxen; Rofecoxib; Etoricoxib;
D O I
暂无
中图分类号
学科分类号
摘要
Chronic pain in the elderly is frequently a result of arthritic disorders, particularly osteoarthritis. The cyclo-oxygenase (COX)-2 inhibitors are as effective as standard NSAIDs for the relief of pain and for improving function in elderly patients with osteoarthritis and rheumatoid arthritis. COX-2 inhibitors increase the risk of serious gastroduodenal adverse reactions but there is evidence that they carry a lower risk for these adverse effects than standard NSAIDs, except when there is concurrent aspirin use. Since gastroduodenal disorders are the most frequently reported serious adverse effects of NSAIDs and these disorders occur more frequently in the elderly, COX-2 inhibitors offer an alternative to standard NSAIDs in this age group. However, they are not appropriate for many patients with cardiovascular and renal disease.
引用
收藏
页码:185 / 200
页数:15
相关论文
共 50 条
  • [1] Cyclo-oxygenase-2 inhibitors - When should they be used in the elderly?
    Savage, R
    DRUGS & AGING, 2005, 22 (03) : 185 - 200
  • [2] Regulation of cyclo-oxygenase-2
    Stack, E
    Dubois, RN
    BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2001, 15 (05) : 787 - 800
  • [3] Cyclo-oxygenase-2 inhibitors
    Husband, Michael
    Mehta, Vivek
    BJA EDUCATION, 2013, 13 (04) : 131 - 135
  • [4] Cyclo-oxygenase-1 and cyclo-oxygenase-2 and cardiovascular system
    Lettino, M
    Cantù, F
    Mariani, M
    DIGESTIVE AND LIVER DISEASE, 2001, 33 : S12 - S20
  • [5] Cyclo-oxygenase-2 inhibitors and cancer
    André, T
    Soria, JC
    BULLETIN DU CANCER, 2004, 91 : S59 - S60
  • [6] Crystallization of recombinant cyclo-oxygenase-2
    Stevens, AM
    Pawlitz, JL
    Kurumbail, RG
    Gierse, JK
    Moreland, KT
    Stegeman, RA
    Loduca, JY
    Stallings, WC
    JOURNAL OF CRYSTAL GROWTH, 1999, 196 (2-4) : 350 - 355
  • [7] Clinical Potential of Cyclo-Oxygenase-2 Inhibitors
    Jaime A. Oviedo
    M. Michael Wolfe
    BioDrugs, 2001, 15 : 563 - 572
  • [8] Cyclo-oxygenase-2 inhibitors and cardiovascular events
    Warner, TD
    Mitchell, JA
    Vane, JR
    LANCET, 2002, 360 (9346): : 1700 - 1701
  • [9] STRUCTURE OF THE HUMAN CYCLO-OXYGENASE-2 GENE
    APPLEBY, SB
    RISTIMAKI, A
    NEILSON, K
    NARKO, K
    HLA, T
    BIOCHEMICAL JOURNAL, 1994, 302 : 723 - 727
  • [10] Polymorphisms in Two Regions of the Cyclo-Oxygenase-2 Gene Associated with Variation in Risk of Coronary Thrombosis with Cyclo-Oxygenase-2 Inhibitors
    Henry, D.
    Lincz, L.
    Attia, J.
    McElduff, P.
    Bisset, L.
    Peel, R.
    Hancock, S.
    Henderson, K.
    Whitaker, D.
    Seldon, M.
    McGettigan, P.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2009, 18 : S116 - S116